Kala Bio vs Pliant Therapeutics
KALA and PLRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KALA and PLRX compare
Pliant Therapeutics is the larger company, worth 16 times as much as Kala Bio ($43.2M against $2.7M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KALA | PLRX |
|---|---|---|
| Size and price | ||
| Market cap | $2.7M | $43.2M |
| Share price | $0.139 | $0.697 |
| Change, 1 year | −99.6% | −61.3% |
| Change, 5 years | −100.0% | −95.4% |
| Beta (5Y) | 0.34 | 1.00 |
| Employees | 6 | 49 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 0.3× |
| FCF yield | – | −155% |
| Profitability | ||
| Return on equity | −345% | −55.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −698.2× |
| Current ratio | 6.88 | 8.05 (better) |
| Altman Z-score | −96.83 | −7.99 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 3.2% | 77.7% |
| Held by insiders | – | 13.0% |
| Insider net buying, 12 months | $0 (better) | −$164K |
| Short interest, % of float | – | 9.1% |
Go deeper
- KALA stock overview
- KALA income statement
- KALA valuation and score
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.